

Craig Shimasaki, PhD, MBA

Co-founder of ViRelieve, Moleculera Labs and BioSource Consulting Group

Dr. Shimasaki is one of four co-founders of ViRelieve, a novel anti-viral therapeutics company based upon innovative technology licensed from HES-SO Valais and the research of Dr. Origène Nyanguile, Vice President of Preclinical Development, along with co-founders Dr. Ivan Ivanov, CEO, and Dr. Filip Yabukarski, Chief Scientific Officer.

Dr. Shimasaki has co-founded nine companies and led five clinical diagnostic tests through FDA 510(k) approval and is a co-inventor on multiple patents. He has over 35 years of biotechnology industry experience, starting his career at Genentech. His research and development work included epitope mapping for an HIV vaccine, SNP-based genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutic and biologic products for infectious and neuropsychiatric diseases. He has been involved in raising over \$30 million for these companies and participated in taking five companies public in the U.S. and Canadian stock markets.

Dr. Shimasaki received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma, Price School of Business and teaches biotechnology entrepreneurship. Dr. Shimasaki has authored and edited two books *“The Business of Bioscience: What Goes Into Making a Biotechnology Product”* and *“Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies.”* His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.